Novel Associations Between Major Histocompatibility Complex and Pediatric-onset Inflammatory Bowel Disease

被引:10
|
作者
Kolho, Kaija-Leena [1 ]
Paakkanen, Riitta [2 ]
Lepisto, Anna [3 ]
Wennerstom, Annika [2 ]
Meri, Seppo [4 ,5 ]
Lokki, Marja-Liisa [2 ]
机构
[1] Univ Helsinki, Childrens Hosp, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Haartman Inst, Transplantat Lab, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Gastrointestinal Surg, FIN-00014 Helsinki, Finland
[4] Univ Helsinki, Dept Bacteriol & Immunol, Immunobiol Res Program, Haartman Inst, FIN-00014 Helsinki, Finland
[5] Helsinki Univ Hosp, Helsinki, Finland
关键词
children; complement C4 deficiency; Crohn disease; human leukocyte antigen; surgery; ulcerative colitis; CROHNS-DISEASE; ULCERATIVE-COLITIS; HLA SYSTEM; PARTS; GENETICS; SARCOIDOSIS; POPULATION; C4; VARIANTS; ALLELE;
D O I
10.1097/MPG.0000000000000984
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: Major histocompatibility complex (MHC) genes have been widely studied in adult inflammatory bowel disease (IBD), but data on MHC genes are scarce in pediatric IBD. This study focused on MHC association of genes with pediatric-onset IBD and its different phenotypes. Methods: Blood samples of 103 patients with pediatric IBD (Crohn disease or ulcerative colitis) were collected at Children's Hospital, University of Helsinki, Finland. HLA-A, -B, -DRB1 alleles and complement C4A and C4B gene copy numbers were determined and constructed into haplotypes by a Bayesian algorithm (PHASE). A general population cohort (n = 149) served as a control. HLA-alleles and C4 deficiency frequencies were compared between patients and controls with chi(2)-squared and Fisher exact test with Bonferroni correction (P-corr). Results: One MHC haplotype HLA-A(*)03; HLA-B(*)07; 1 C4A gene; 1 C4B gene; HLA-DRB1(*)15 was more common in Crohn disease and ulcerative colitis than in controls (7/61, 11.5%, 6/42, 14.3% and 1/149, 0.7%, respectively, odds ratio (OR) = 19.19, 95% CI 2.31-159.57, P-corr = 0.004 for Crohn disease vs controls and OR = 24.67, 95% CI 2.88-211.36, P-corr = 0.002 for ulcerative colitis vs controls). Two MHC markers were associated with clinical characteristics. HLA-DRB1(*)01 was more common in patients with milder disease course, that is, no need for anti-tumor necrosis factor (TNF)-alpha medication (18/32, 56.2% vs 19/71, 26.8% without and with anti-TNF-alpha medication, respectively, OR = 0.28, 95% CI 0.12-0.68, P-corr = 0.032). C4B deficiency (C4B genes) was associated with complicated recovery after surgery (12/16, 75.0% vs 4/16, 25.0%, respectively, OR = 9.00, 95% CI 1.82-44.59, P-corr = 0.025). Conclusions: One MHC haplotype is strongly linked with pediatric-onset IBD, whereas the need for immunomodulatory therapy and surgery outcome associates with other distinct MHC gene markers.
引用
收藏
页码:567 / 572
页数:6
相关论文
共 50 条
  • [31] Peripheral Blood Monocytosis Is Associated With Long-Term Disease Severity in Pediatric-Onset Inflammatory Bowel Disease
    Zhang, Xiaoyi
    Ramos-Rivers, Claudia
    Prathapan, Krishnapriya
    Wang, Xianling
    Tang, Gong
    Kim, Sandra
    Binion, David G.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 76 (06): : 756 - 762
  • [32] Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting
    Hemming-Harlo, Maria
    Merras-Salmio, Laura
    Nikkonen, Anne
    Kolho, Kaija-Leena
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (01) : 313 - 322
  • [33] Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study
    Rebus, Soleynne
    Coopman, Stephanie
    Djeddi, Djamal
    Vanrenterghem, Audrey
    Dupont, Claire
    Lacotte, Edouard
    Ley, Delphine
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2025, 80 (01): : 113 - 123
  • [34] Early Life Oral Antibiotics Are Associated With Pediatric-Onset Inflammatory Bowel Disease-A Nationwide Study
    Jawad, Ali Bashir
    Jansson, Sabine
    Wewer, Vibeke
    Malham, Mikkel
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2023, 77 (03): : 366 - 372
  • [35] Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood
    Guz-Mark, Anat
    Rinawi, Firas
    Egotubov, Oxana
    Shimon, Ilan
    Shamir, Raanan
    Assa, Amit
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 639 - 642
  • [36] Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease
    C J Cardinale
    Z Wei
    S Panossian
    F Wang
    C E Kim
    F D Mentch
    R M Chiavacci
    K E Kachelries
    R Pandey
    S F A Grant
    R N Baldassano
    H Hakonarson
    Genes & Immunity, 2013, 14 : 447 - 452
  • [37] Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting
    Maria Hemming-Harlo
    Laura Merras-Salmio
    Anne Nikkonen
    Kaija-Leena Kolho
    European Journal of Pediatrics, 2024, 183 : 313 - 322
  • [38] Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Danish Cohort Study
    Kjaergaard, Victoria S.
    Jensen, Camilla B.
    Elmahdi, Rahma
    Burisch, Johan
    Allin, Kristine H.
    Jess, Tine
    GASTROENTEROLOGY, 2020, 159 (04) : 1609 - 1611
  • [39] The characteristics of pediatric-onset inflammatory bowel disease based on our 20-year-long study
    Tobi, Luca
    Cseh, Aron
    ORVOSI HETILAP, 2025, 166 (11) : 403 - 412
  • [40] Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease
    Cardinale, C. J.
    Wei, Z.
    Panossian, S.
    Wang, F.
    Kim, C. E.
    Mentch, F. D.
    Chiavacci, R. M.
    Kachelries, K. E.
    Pandey, R.
    Grant, S. F. A.
    Baldassano, R. N.
    Hakonarson, H.
    GENES AND IMMUNITY, 2013, 14 (07) : 447 - 452